GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Arena Pharmaceuticals, Inc. (ARNA) [hlAlert]

Rating:
Buy ARNA
down 65.85 %

Arena Pharmaceuticals, Inc. (ARNA) rated Buy with price target $16 by Banc of America Sec

Posted on: Tuesday,  Jan 15, 2008  8:25 AM ET by Banc of America Sec

Banc of America Sec rated Buy Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) on 01/15/2008, when the stock price was $7.76.
Since then, Arena Pharmaceuticals, Inc. has lost 65.85% as of 10/08/2015's recent price of $2.65.
If you would have followed this Banc of America Sec's recommendation on ARNA, you would have lost 65.85% of your investment in 2823 days.

Arena Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena's most advanced product candidate, lorcaserin, is being investigated in a Phase three clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Integrity, objectivity and originality are cornerstones of the value–added research that we offer to corporate and institutional clients. As thought leaders, our goal is to help clients understand and adapt to changing economic conditions and events that drive markets, currencies, industries and companies worldwide. And we deliver innovative ideas based on rigorous primary research, sound principles and clear vision. Our research teams are organized by areas of expertise, from equities, fixed income and emerging markets to foreign exchange and global financial risk advisory – featuring many of the industry’s most respected analysts and economists. Through our private, password–protected Web portal, our clients have access to a comprehensive array of timely research and commentary, including: * U.S. and global economic updates and indicators * Federal budget and fiscal policy * Industry outlooks * Stock coverage and picks * Financial market strategies * Corporate bond issuer risk analysis
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/15/2008 8:25 AM Buy
None
7.76 16.00
as of 12/24/2008
1 Week down  -4.65 %
1 Month down  -39.55 %
3 Months down  -26.78 %
1 YTD down  -41.00 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy